Culture

Antibiotic resistance may spread even more easily than expected

image: Transfer of antibiotic resistance genes to pathogenic bacteria in humans may be much more boundless and widespread than previously expected. The resistance genes may be transferred from numerous bacterial species in habitats such as aquatic environments, animals, industries and soil.

Image: 
Jan Zrimec/Chalmers University of Technology

Pathogenic bacteria in humans are developing resistance to antibiotics much faster than expected. Now, computational research at Chalmers University of Technology, Sweden, shows that one reason could be significant genetic transfer between bacteria in our ecosystems and to humans. This work has also led to new tools for resistance researchers.

According to the World Health Organisation, antibiotic resistance is one of the greatest threats to global health, food safety and development. It already causes over 33,000 deaths a year in Europe alone.

Completely different species of bacteria can spread resistance genes to each other through plasmids - small DNA molecules where bacteria store some of their genes outside the chromosome. When two bacterial cells come into contact, they can copy plasmids to each other. This is called conjugation, and it is the most important mechanism for spreading antibiotic resistance.

"In recent years, we've seen that resistance genes spread to human pathogens to a much greater degree than anyone expected," says Jan Zrimec, researcher in systems and synthetic biology at Chalmers University of Technology. "Many of the genes appear to have originated in a wide array of bacterial species and environments, such as soil, water and plant bacteria.

"This has been difficult to explain, because although conjugation is very common, we've thought that there was a distinct limitation for which bacterial species can transfer plasmids to each other. Plasmids belong to different mobility groups, or MOB groups, so they can't transfer between just any bacterial species.

Zrimec has developed new methods of data analysis that show that genetic transfer may be much more boundless and widespread than previously expected.

Among other things, he has developed an algorithm that can identify specific DNA regions that are necessary for conjugation - called oriT regions - in large amounts of data consisting of genetic sequences from the DNA of thousands of plasmids. The algorithm can also sort plasmids into MOB groups based on the identified oriT regions.

He has used the algorithm to explore known gene sequences from over 4,600 naturally occurring plasmids from different types of bacteria, which has not been possible to do systematically before. The results show, among other things, that:

The number of oriT regions may be almost eight times higher than those found with the standard method used today.

The number of mobile plasmids may be twice as high as previously known.

The number of bacterial species that have mobile plasmids may be almost twice as high as previously known.

Over half of these plasmids have oriT regions that match a conjugation enzyme from another plasmid that has previously been classified in a different MOB group. This means that they could be transferred by one of these plasmids that happens to be in the same bacterial cell.

The last part means that there may be transfer mechanisms between large numbers of bacterial species and environments where we previously believed there were barriers.

"These results could imply that there is a robust network for transferring plasmids between bacteria in humans, animals, plants, soil, aquatic environments and industries, to name a few," Zrimec explains. "Resistance genes occur naturally in many different bacteria in these ecosystems, and the hypothetical network could mean that genes from all of these environments can be transferred to bacteria that cause disease in humans.

"This may be a possible reason for the rapid development of resistance in human pathogens that we have observed in recent years. Our extensive use of antibiotics selects for resistance genes, which could thus flow in from a much larger naturally occurring genetic reservoir than we previously estimated."

The results need to be verified experimentally in the future, but the data analysis methods Zrimec developed can already be employed by many of the researchers working with antibiotic resistance in various medical and biological fields. They provide a powerful new tool for systematically mapping out the potential transferability of different plasmids.

"This has been a major limitation of the research field up to now," Zrimec says. "I hope that the methods will be able to benefit large parts of the research into antibiotic resistance, which is an extremely interdisciplinary and fragmented area. The methods can be used for studies aiming to develop more effective limitations to antibiotic use, instructions for how antibiotics are to be used and new types of substances that can prevent the spread of resistance genes at the molecular level."

More about: Genetic transfer through conjugation:

In order for conjugation to start, an enzyme is needed - a relaxase - which fits onto a specific location on the plasmid. The relaxase has to recognise and bind to a region where the DNA ring can be nicked and a strand can be transferred to the next bacterium. This DNA region is called the origin of transfer, or oriT.

Previously, it was thought that an individual plasmid must contain both the gene for the relaxase and a matching oriT in order to be transferred to other bacteria. But a bacterial cell can contain several plasmids, and in recent years various researchers have shown that a relaxase from one plasmid can fit with an oriT region on another plasmid in the same cell and activate the conjugation of that plasmid.

This means that it may be enough for a plasmid to have only an oriT to be able to conjugate, which in turn means that many plasmids that have previously been classed as nonmobile, because they lack the relaxase gene, can be conjugative. But until now it has not been known how common the phenomenon is among bacteria. This is one of the knowledge gaps that Zrimec's results are helping to fill in.

More about: The new method compared with the current standard:

The current standard tools for assessing the transferability of plasmids are based on searching for the DNA sequences for the relaxase enzyme or for oriT regions that the enzyme can bind to. There are several key limitations to this. For one, some tools produce incomplete results, while others require extremely time-consuming and resource-demanding laboratory tests.

Zrimec's new data analysis method is based solely on identifying oriT regions, using special physiochemical properties found specifically in oriT regions of DNA. Through previous research, he has shown that these physiochemical signatures - which determine which relaxase can bind to the oriT region - are more stable and specific than the DNA sequences themselves. This allows the classification of the plasmids to the right MOB group based on the oriT region, independently of relaxase, which also allows researchers to map out the overall transferability between different bacterial species and environments.

The method can manage large amounts of data and can be used to search effectively for oriT regions on plasmids in their entirety.

Credit: 
Chalmers University of Technology

Mayo Clinic study indicates age influences sex-related outcomes after heart attack

ROCHESTER, Minn. -- Approximately 1.5 million heart attacks and strokes occur every year in men and women in the U.S. Sex and age play a large part in who experiences a heart attack, the methods used to treat these heart attacks, and the eventual post hospital outcomes of the people who experience heart attacks. Mayo Clinic researchers discuss these sex and age differences in study findings published in Mayo Clinic Proceedings.

In this study, Mayo Clinic researchers wanted to see if age was a key factor in sex-related differences in patients with a heart attack. Using public all-payer hospitalization data from the Nationwide Inpatient Sample, the team of researchers evaluated more than 6.7 million hospitalization records for heart attacks. They categorized the information by sex and divided the patients into four age categories: under 45, 45-64, 65-84 and over 84.

To fully compare the treatment given, patients were further categorized by the type of their heart attack. With a STEMI, or ST elevation myocardial infarction heart attack, there is a complete blockage of an artery supplying blood to the heart. With a NSTEMI, or non-ST elevation myocardial infarction heart attack, there is no ST elevation, but there is typically a significant but partial artery blockage.

The findings show several main points regarding sex and age differences, according to Mohamad Adnan Alkhouli, M.D., an interventional cardiologist at Mayo Clinic and first author of the study.

Women had fewer acute heart attacks than men across all age groups. However, because there are more women than men over 84, more women had heart attacks in that age group. In the NSTEMI and STEMI groups, women had distinctive differences in their risk profiles for heart disease, compared to men. Women were more likely to have hypertension, diabetes, anemia, atrial fibrillation, chronic lung disease and previous stroke. However, women were less likely than men to have had a previous heart attack and less likely to have an implantable defibrillator, a previous revascularization or experience cardiogenic shock.

The data show a clear difference between the sexes for managing a heart attack in the hospital. In the NSTEMI group, women of any age were less likely than men to undergo coronary angiography imaging of the heart's blood vessels, angioplasty to open clogged arteries with a balloon catheter, coronary artery bypass grafting to redirect blood flow, or receive mechanical circulatory support. In the STEMI group, women were also less likely to have coronary angiography or primary angioplasty, or receive mechanical circulatory support. This was true across all age groups.

Compared with men, the data show that worse hospital outcomes among women are confined to those who are younger. In the NSTEMI group, women under 65 were more likely than men to die at the hospital because of their heart attack. This difference in mortality in women versus men also was observed in patients under 85 in the STEMI group. For both categories of heart attack, younger women were more likely to have vascular complications and major bleeds, although the same was not true for stroke and acute kidney injury.

"These data suggest that younger women are particularly at higher risk of major complications after a heart attack and therefore should be the focus of further research to identify strategies to mitigate this increased risk," says Dr. Alkhouli.

Credit: 
Mayo Clinic

Severe menopause symptoms often accompany premature ovarian insufficiency

CLEVELAND, Ohio (Jan. 20, 2021)--Hot flashes, insomnia, and vaginal dryness are commonly reported symptoms that accompany the menopause transition. A new study suggests that such symptoms--especially psychological and sexual problems--are worse for women who have premature ovarian insufficiency (POI) than for women undergoing natural menopause. Study results are published online today in Menopause, the journal of The North American Menopause Society (NAMS).

Premature ovarian insufficiency is defined as the cessation of ovarian function that leads to menopause before the age of 40 years. The condition is associated with increased risks for a number of long-term health comorbidities, including osteoporosis, cardiovascular disease, mood disorders, cognitive impairment, and sexual dysfunction. It can also lead to a shorter life expectancy.

Despite research around the various risk factors associated with POI, few studies have examined the effect of POI relative to the prevalence, severity, and factors affecting menopause symptoms. In this new study involving nearly 300 Chinese women, researchers specifically investigated menopause symptoms in women with POI and compared them with the severity and prevalence of similar symptoms in women who experienced natural menopause.

What they found was that women with POI experience a high prevalence of menopause symptoms, especially those in the psychological and sexual domains, and that these symptoms are often more severe than those experienced by women who undergo natural menopause. The symptoms likely to be most severe include mood swings, hot flashes, insomnia, fatigue, and sexual dysfunction (including vaginal dryness, dyspareunia, and decreased libido).

On the basis of these results, the researchers have suggested that healthcare providers be more cognizant of psychological complications and sexual dysfunction risks in women with POI and work with them to identify options for relief.

Results are published in the article "Menopausal symptoms in women with premature ovarian insufficiency: prevalence, severity and associated factors."

"This study of Chinese women showed that those with POI had more prevalent menopause-related symptoms than women with menopause at the average age. It is important to note that regardless of the prevalence or severity of symptoms, women with POI should receive hormone therapy at least until the average age of menopause unless there are contraindications to its use in order to mitigate potential long-term adverse health effects, including fractures, heart disease, cognitive impairment, and early mortality--in addition to mood disturbances and sexual dysfunction," says Dr. Stephanie Faubion, NAMS medical director.

Credit: 
The Menopause Society

Making microwaves safer for children

A 15-year research and advocacy effort to make microwave ovens safer has led to a change in national manufacturing standards that will make microwaves more difficult for young children to open, protecting them from the severe microwave-related burns that scar hundreds of kids under 5 years old in the United States each year. Researchers at Rush University Medical Center and other leaders of the campaign, who worked diligently to document the frequency and severity of these injuries and young children's vulnerability to them, published the results of their efforts in The Journal of Pediatrics on Jan. 20.

"The efforts we have made over the last 15 years have recently led to a change in how microwaves are made. In 2023, manufacturers will be required to incorporate two distinct actions into opening the door of a microwave oven," said Kyran Quinlan MD, MPH, a professor of pediatrics and the director of the Division of General Pediatrics at Rush University Medical Center. Quinlan and fellow Rush pediatrician Gina Lowell, MD, worked closely with colleagues from the University of Chicago Medical Center Burn Unit to achieve the goal of child resistant microwave doors.

"We believed that if young children were less able to open microwave oven doors, they would be less likely to be able to remove the heated items, such as liquids and noodle soups, and they would therefore be less at risk for severe burns," Quinlan added. 'These burns are terribly painful, require burn unit care, and can be life-changing because of the permanent scarring that often results."

An abstract presenting the results from the advocacy effort was chosen as the Program Description Abstract of the Year during the annual conference of the Injury Free Coalition for Kids in December 2019.

According to the American Burn Association, 22.5% of the patients in burn units across the United States are children, and most of the children are admitted for scalds rather than burns suffered in fires.

The researchers' 15-year journey began with documenting the issue, and learning how microwave ovens are regulated and how to effectively advocate for child-resistant microwave oven doors. In 2008, the researchers published an analysis of three years of burn unit data that found that a significant percentage of burns involved young children opening a microwave themselves and removing and spilling the oven's heated contents.

In that report, the youngest child burned was 18 months old, and nearly half of the cases required skin grafts -- a process of removing skin from one part of the body to cover the section of skin that was burned.

The researchers then evaluated and documented the abilities of healthy young children ages 15 months to 4 years to use microwave ovens. They recorded whether the children could open the microwave oven door with either a push mechanism or a pull mechanism, turn on the microwave and remove its contents.

The study revealed that children as young as 17 months could open both a push- and a pull-open microwave oven door, remove what was in the microwave, and even turn it on. Nearly all children were able to perform each of these tasks by the age of 2.

The researchers then worked to submit a proposed change in the design requirements of microwave oven doors to make them more difficult for young children to open. Quinlan and Lowell worked with the child product safety advocacy group Kids in Danger to enlist college engineering students to design child-resistant microwave doors to demonstrate their feasibility. The team also presented their research at national meetings and created a short video to put a face with the statistics about microwave-related childhood burns.

Eventually, Quinlan and Marla Robinson MSc, OTR/L, assistant director of therapy services at University of Chicago Medical Center and a partner in the advocacy campaign, became voting members of the Underwriters Laboratories Standards Technical Panel for microwave ovens, which sets the standards required for any microwave sold in the United States.

After previous failed attempts to change the standard for microwave oven doors, the panel passed the change by a single vote in September 2018. The new microwave ovens also will be required to include labels warning families of the risk of severe scalds to young children.

"Early on, we felt that making microwave oven doors harder to open would truly protect young children from these burns, which were frequently severe," Quinlan said. "This took longer than we expected, but it was so worth it.

"We knew we had work to do to share this idea and to provide enough information to convince others who could be a part of the change we sought, but ultimately, our idea was a good one, and with persistence we realized our goal."

Credit: 
Rush University Medical Center

Breakthrough in understanding 'tummy bug' bacteria

image: Scanning Electron Microscope (SEM) image of healthy, growing Vibrio parahaemolyticus.

Image: 
University of Exeter Bioimaging Unit

Scientists have discovered how bacteria commonly responsible for seafood-related stomach upsets can go dormant and then "wake up".

Vibrio parahaemolyticus is a marine bacterium that can cause gastroenteritis in humans when eaten in raw or undercooked shellfish such as oysters and mussels.

Some of these bacteria are able to turn dormant in poor growth conditions such as cold temperatures - and can remain in that state of hibernation for long periods before resuscitating.

University of Exeter scientists have identified a population of these dormant cells that are better at waking up, and have discovered an enzyme involved in that waking up process.

"Most of these bacteria die when they encounter poor growth conditions, but we identified sub-populations of bacteria that are able to stay dormant for long periods of time," said lead author Dr Sariqa Wagley, of the University of Exeter.

"We found that this population has a better ability to revive when conditions improve.

"Our tests show that when these dormant bacteria are revived they are just as virulent and able to cause disease."

The findings could have implications for seafood safety, as dormant cells are not detectable using routine microbiological screening tests and the true bacterial load (amount of bacteria) could be underestimated.

"When they go dormant, these bacteria change shape, reduce respiration activities and they don't grow like healthy bacteria on agar plates used in standard laboratory tests, so they are much harder to detect," Dr Wagley explained.

"Using a range of tools, we were able to find dormant bacteria in seafood samples and laboratory cultures and look at their genetic content to look for clues in how they might survive for long periods.

"It is important to note that thorough cooking kills bacteria in seafood.

"Our results may also help us predict the conditions that dormant bacteria need in order to revive."

Working with the seafood industry, the Exeter team identified a lactate dehydrogenase enzyme that breaks down lactic acid into pyruvate, a key component of several metabolic pathways (chemical reactions in a cell).

The findings suggest that lactate dehydrogenase is essential both for maintaining bacterial dormancy and resuscitation back to an active form.

Vibrio parahaemolyticus usually grows in warm and tropical marine environments, although Dr Wagley said that due to rising sea temperatures in recent years it is now prevalent in UK waters during the summer months.

During the winter, it is not detected in the marine environment around the UK and it is thought to die due to the cold winter temperatures.

This study could explain how Vibrio parahaemolyticus is able remerge in the environment during the summer.

Credit: 
University of Exeter

New Parkinson's disease therapeutics discovered by Ben-Gurion U researchers

BEER-SHEVA, Israel...January 20, 2021 -Ben-Gurion University of the Negev researchers have discovered that the protein BMP5/7 offers promising therapeutics that could slow down or halt the progression of Parkinson's disease.

The findings were published in the prestigious clinical neurology journal, Brain.

Parkinson's disease, which affects over one million people in U.S. and 10 million worldwide, causes tremors and severe movement impairment due to progressive degeneration of dopamine-producing brain cells. It is believed that the protein "alpha-synuclein," present in all human brains, misfolds and forms toxic clumps in these cells, which causes the disease.

While current Parkinson's disease therapies improve symptoms, they are not effective in advanced illness stages and, unfortunately, do not slow or cure the disease.

Dr. Claude Brodski, M.D., head of the BGU's Laboratory for Molecular Neuroscience, discovered that BMP5/7 signaling in neurons was significantly reduced in dopamine-producing brain cells, which could contribute to Parkinson's disease advancement.

"Indeed, we found that BMP5/7 treatment can, in a Parkinson's disease mouse model, efficiently prevent movement impairments caused by the accumulation of alpha-synuclein and reverse the loss of dopamine-producing brain cells," says Dr. Brodski. "These findings are very promising, since they suggest that BMP5/7 could slow or stop Parkinson's disease progression. Currently, we are focusing all our efforts on bringing our discovery closer to clinical application."

BGN Technologies, Ben-Gurion University's technology transfer company, has filed several patent applications covering this breakthrough discovery.

Dr. Galit Mazooz Perlmuter, senior vice president of business development, bio-pharma at BGN Technologies, notes, "There is a vast need for new therapies to treat Parkinson's disease, especially in advanced stages of the disease. Dr. Brodski's findings, although still in their early stages, offer a disease-modified drug target that will address this devastating condition. We are now seeking an industry partner for further development of this patent pending invention."

Credit: 
American Associates, Ben-Gurion University of the Negev

NEWS2 evaluated for prediction of severe COVID-19 outcome in large international study

In the first systematic large-scale evaluation of the UK National Early Warning Risk Score (NEWS) 2 as a scoring system for predicting severe COVID-19 outcomes in patients, researchers at King's College London have found poor-to-moderate accuracy for identifying patients at risk of being transferred to intensive care units (ICUs) or dying after 14 days of hospitalisation. Accuracy of predictions in short term (three days) showed moderate success.

For people who are hospitalised with severe COVID-19, it is vital to quickly identify which patients may deteriorate and require transfer to an intensive care unit (ICU) for organ support or may die. NEWS2 is an early warning score that combines physiological parameters such as respiration rate, oxygen saturation, blood pressure and temperature. NEWS2 is currently used almost universally in UK NHS Trusts to identify which patients are at risk of deteriorating early.

The paper was published today (Thursday 21 January) in BMC Medicine.

Accuracy of NEWS2

Researchers analysed data from 1,276 COVID-19 patients admitted to King's College Hospital NHS Foundation Trust during the first wave in March-April 2020. The team then validated their models using data for over 6,000 patients across eight other hospitals globally (five in the UK, one in Norway, and two in China). At all UK sites, around one third of patients with COVID-19 were transferred to ICU or died within 14 days of hospital admission.

The researchers evaluated how well patients' NEWS2 scores measured at hospital admission anticipated who would have severe COVID-19 outcomes, which means either being transferred to ICU or dying. In all UK sites, combining NEWS2 and age to predict outcomes showed moderate success in the short term (three days), but for poor-to-moderate success for medium-term (14 days) outcomes.

Dr Ewan Carr, Statistician Research Fellow at the Institute of Psychiatry, Psychology & Neuroscience, King's College London, and co-lead author said: "We have conducted the largest study to date evaluating the accuracy of NEWS2 for predicting medium-term COVID outcomes. NEWS2 is widely used in UK NHS trusts but little is known about how well it can predict severe COVID outcomes and so evaluating its accuracy is important as we look to improve patient care now and in future.

By collecting data from nine hospitals globally, our results have robust external validation. We found consistency across sites both in the performance of NEWS2 alone, as well as for the supplemented model. In short, NEWS2 tended to have poor-moderate performance but was improved by adding common blood and physiological measures."

The research team used CogStack, an existing platform developed by NIHR Maudsley BRC and in use at King's College Hospital NHS Foundation Trust, which allows for rapid extraction and processing of data from patient's electronic health records.

Professor Richard Dobson, Head of the Department of Biostatistics & Health Informatics, NIHR Maudsley BRC, said: "The CogStack platform allows us to extract information from deep within hospital records at King's College Hospital NHS Foundation Trust in real time in order really explore complex questions such as this. This includes being able to extract information relating to co-morbidities, for example, that may only be mentioned in passing in the physician narrative"

Improving predictive ability

Researchers found that accuracy in predicting severe outcomes was improved by considering routinely-collected blood and physiological parameters from patients including age, oxygen saturation and neutrophil count, which is an important infection-fighting immune system cell. In models that supplemented NEWS2 with these parameters the ability to predict severe outcomes was improved.

Dr James Teo, Consultant Neurologist at King's College Hospital and Clinical Director of Data Science and lead of CogStack platform, said: "Our results for the first time validates NEWS2, and shows how it could be improved by adding common blood and physiological parameters. Thankfully, this NHS scoring system is easy to adapt and implement in real-world clinical practice, compared to other complex risk-scoring models.

I, alongside all the authors and collaborators, would like to thank the guidance and contributions of the patients and members of the King's Electronic Records Research Interface that made this all possible."

Credit: 
NIHR Maudsley Biomedical Research Centre

On the origins of money: Ancient European hoards full of standardized bronze objects

image: Ribs (Spangenbarren)

Image: 
M.H.G. Kuijpers, author photo (CC-BY 4.0, https://creativecommons.org/licenses/by/4.0/)

In the Early Bronze Age of Europe, ancient people used bronze objects as an early form of money, even going so far as to standardize the shape and weight of their currency, according to a study published January 20, 2020 in the open-access journal PLOS ONE by Maikel H. G. Kuijpers and C?t?lin N. Popa of Leiden University, Netherlands.

Money is an important feature of modern human society. One key feature of money is standardization, but this can be difficult to identify in the archaeological record since ancient people had inexact forms of measurement compared with today. In this study, the authors assessed possible money from the Early Bronze Age of Central Europe, comparing the objects based on their perceived - if not precise - similarity.

The objects studied were made of bronze in shapes described as rings, ribs, and axe blades. The authors examined more than 5,000 such objects from more than 100 ancient hoards. They statistically compared the objects' weights using a psychology principle known as the Weber fraction, which quantifies the concept that, if objects are similar enough in mass, a human being weighing them by hand can't tell the difference.

They found that even though the objects' weights varied, around 70% of the rings were similar enough to have been indistinguishable by hand (averaging about 195 grams), as were subsets of the ribs and axe blades.

The authors suggest that this consistent similarity in shape and weight, along with the fact that these objects often occurred in hoards, are signs of their use as an early form of standardized currency. Later, in the Middle Bronze Age of Europe, more precise weighing tools appear in the archaeological record along with an increase in scrap bronze, pointing to a developed system of weighing.

The authors add: "The euros of Prehistory came in the form of bronze rings, ribs and axes. These Early Bronze Age artefacts were standardized in shape and weight and used as an early form of money."

Credit: 
PLOS

Late rainy season reliably predicts drought in regions prone to food insecurity

image: Top: Whisker plots describing the variability of correlation between timing of onset of the rainy season (onset date) and peak NDVI (indicator of drought) in the following months for East, West, and Southern Africa based on Acute Food Insecurity (AFI) risks (Table 1). Bottom: Scatter plots of standardized anomaly of onset date timing and peak NDVI for the AU2s with the highest AFI risks. *The number on the top of box-whisker plots indicate the number of AU2 in each of the corresponding bins. AFI risk level 1 indicates lowest risk of food insecurity and level 5 indicates highest risk, further explanation for AFI risk level can be found in Table 1.

Image: 
Shukla et al, PLOS ONE 2021 (CC-BY 4.0, https://creativecommons.org/licenses/by/4.0/)

The onset date of the yearly rainy season reliably predicts if seasonal drought will occur in parts of Sub-Saharan Africa that are particularly vulnerable to food insecurity, and could help to mitigate its effects. Shraddhanand Shukla and colleagues at the University of California, Santa Barbara's Climate Hazards Center, present these findings in the open-access journal PLOS ONE on January 20, 2021.

Climate-driven seasonal drought can impact crop yields and is among major contributors to food insecurity, which can threaten people's lives and livelihoods. In the last five years, parts of Sub-Saharan Africa have experienced a significant rise in food insecurity, sometimes requiring emergency food assistance. Early warning systems that reliably predict conditions likely to lead to food insecurity could help drive timely actions to mitigate these effects.

Shukla and colleagues hypothesized that the onset date of the rainy season, as calculated from precipitation data, could serve as such a warning. To explore this possibility, they analyzed the relationship between the onset date, drought conditions observed via satellite images of vegetation cover, and the risks of food insecurity based on quarterly reports on food insecurity in across Sub-Saharan Africa from April 2011 through February 2020.

The analysis showed that a delay of about 10 days from the median date of onset of the rainy season was associated with a significantly higher likelihood of seasonal drought in regions with the highest risk of acutesevere food insecurity. A 20-day delay indicated a 50 percent chance of drought in those regions. Further analysis confirmed the predictive relationship between rainy season onset date and drought risk across Sub-Saharan Africa as a whole, and particularly in East Africa.

These findings suggest that the onset date of the rainy season could be an important component of an early warning system for droughts likely to lead to food insecurity in Sub-Saharan Africa. Further research could examine the relationship between onset date and other food insecurity indicators, such as high-resolution data on crop yields and prices or mid-season livestock prices.

The authors add: "Timing of rainfall onset can be tracked using remotely sensed observations and forecasted using climate models, and the results of this study show that it can be a reliable indicator of agricultural droughts, particularly in the most food insecure regions of Sub-Saharan Africa, which makes it a simple yet powerful tool to support effective early warning of food insecurity, thus saving lives and livelihood."

Credit: 
PLOS

Antibiotics combinations used regularly worldwide--but 80% of these not recommended by WHO

Fixed dose combinations of antibiotics are consumed in huge quantities globally, but 80 percent of combinations are not on the WHO Essential Medicines List, and 92 percent are not FDA-approved, - with inappropriate combinations risking inefficacy, toxicity, and selection for antimicrobial resistance

Credit: 
PLOS

New antifungal compound from ant farms

Attine ants are farmers, and they grow fungus as food. Pseudonocardia and Streptomyces bacteria are their farmhands, producing metabolites that protect the crop from pathogens. Surprisingly, these metabolites lack common structural features across bacteria from different geographic locations, even though the ants share a common ancestor. Now, researchers report in ACS Central Science they have identified the first shared antifungal compound among many of these bacteria across Brazil. The compound could someday have medical applications.

Attine ants originated as one species at a single location in the Amazon 50 million years ago. They have evolved to 200 species that have spread their farming practices throughout South and Central America. In exchange for food, bacteria at these farms produce small molecules that hold pathogenic fungi such as Escovopsis in check. However, these molecules differ from region to region, suggesting a highly fragmented and geographically limited evolutionary history for the bacteria. Monica T. Pupo, Jon Clardy and colleagues wanted to find out if any antifungal bacterial metabolites with broader distribution had been overlooked in prior investigations.

In a study of bacteria from ant nests at multiple sites in Brazil, the team discovered that nearly two thirds of Pseudonocardia strains produced a potent antifungal agent, which they called attinimicin. This discovery marked the first report of a specialized metabolite with broad geographic distribution produced by ant-associated bacteria. While this metabolite was safe for the fungal crop, it inhibited growth of fungal parasites, though -- unlike many antibiotics -- only in the absence of iron. It was also effective in fighting a Candida albicans infection in mice, comparable to azole-containing antifungal treatments that are used clinically, making it a potential drug candidate. The researchers ascertained attinimicin's structure and studied its evolutionary relationship to two similar bacterial peptides produced by Streptomyces -- oxachelin A and cahuitamycin A. The results suggest the associated genes in the two types of bacteria came from a common ancestor.

Credit: 
American Chemical Society

Researchers uncover potentially promising therapeutic combination for renal cell carcinoma

Boston, Mass. -- Renal cell carcinoma (RCC) is the most common form of cancer of the kidney. In 2018, there were an estimated 403,000 new cases of RCC and 175,000 deaths due to kidney cancer worldwide. Currently, the 5-year survival rate for patients with metastatic RCC is only about 12 percent. Current treatments include inhibitors of the VEGF and PD-1 pathways. However, resistance to therapy occurs in most patients and new combination treatments are still needed to enhance the efficacy of these current approaches.

Now, investigators have demonstrated that ACE2 expression is a good prognostic factor in RCC, that loss of ACE2 mediates resistance to classical treatments, and that in preclinical models, treatment with a drug that is downstream of ACE2 can improve tumor responses in RCC and significantly prolong survival. The team, led by Beth Israel Deaconess Medical Center's (BIDMC) Rupal Bhatt, MD, PhD, and University College Cork, Ireland's Thomas Walther, PhD, published their findings in the journal Science Translational Medicine.

"Our team reported that ACE2 is a new protective molecule for RCC, and building on this finding, we show that angiotensin-(1-7), a small peptide generated by ACE2, can be used to control tumor growth in preclinical models," said co-corresponding Bhatt, a medical oncologist at BIDMC and associate professor of medicine at Harvard Medical School. "Our findings suggest that angiotensin-(1-7) could be developed in clinical trials as a promising therapeutic option in patients with RCC in combination with current standard of care treatments and has a strong potential to improve overall survival."

ACE2 is an enzyme that belongs to the renin-angiotensin system (RAS) and antagonizes the classical angiotensin II/AT1 receptor pathway. Interestingly, it is also the receptor for the SARS-CoV2 spike protein, and its downregulation by the virus leads to the often deadly progression of acute respiratory distress syndrome in COVID-19 patients.

Bhatt, Walther and colleagues show that higher ACE2 expression correlates with better overall survival in patients with RCC. They also demonstrated that VEGF receptor inhibitors such as sunitinib and axitinib down-regulate ACE2 expression in tumor cells in culture and in tumors in mouse models of RCC. Using novel and innovative methods and techniques, the authors generated multiple lines of evidence that this ACE2 down-regulation can be causative for the resistance to VEGF pathway inhibition, the inevitable consequence of this approved used class of drugs.

The authors also report that angiotensin-(1-7) is the likely mediator of this effect. The authors also showed that triple therapy of VEGF pathway inhibitors and anti-PD-L1 with angiotensin-(1-7) is superior to the actual standard treatment with VEGR and PD-1 pathway inhibition.

"Our work shows that angiotensin-(1-7) could provide a promising therapeutic option in patients with RCC in combination with VEGF-pathway inhibitors," said co-corresponding author Walther, Professor in Pharmacology at the University College Cork. "Resistance to VEGF-pathway inhibitors is a general problem in cancer treatment and therefore our findings have broader implications for VEGF-pathway inhibitor therapies that beyond RCC could be extended to other types of cancers."

Credit: 
Beth Israel Deaconess Medical Center

Cats love silver vine and catnip for a more practical reason than developing euphoria

image: A cat responds to silver vine leaves.

Image: 
Masao Miyazaki & Reiko Uenoyama

Catnip and silver vine have been known as cat attractant plants. Cat lovers use dry leaves of these plants and toys stuffed with the leaves to give joy to their pet cats. But how does this work? What is the biological significance of the responsive behavior? A research group at Iwate University, Nagoya University, Kyoto University, and University of Liverpool found that the behavior had more practical reasons than getting euphoria.

"The first appearance of silver vine ("Matatabi" in Japanese) as a cat attractant in literature in Japan dates back to more than 300 years ago. A folklore Ukiyo-e drawn in 1859 shows a group of mice trying to tempt some cats with a smell of silver vine. Still, benefits of the cats' response had remained unknown." says Prof. Masao Miyazaki of Iwate University, a leader of the research project.

The research group first identified the active ingredient of silver vine that induces the response. They isolated substances from extract of silver vine leaves and administrated each of them to cats to examine the response. The experiment revealed that nepetalactol, a novel substance, most strongly induces the characteristic behavior.

"We applied nepetalactol to laboratory paper filters and tested with eighteen laboratory and seventeen feral cats. They displayed the typical response to silver vine. We also tested the substance with larger, non-domestic cats (jaguar, Amur leopard, and Eurasian lynx). They showed a similar reaction. We concluded nepetalactol is responsible for the typical feline reaction to silver vine," said Reiko Uenoyama, the paper's first author.

The second important finding by the researchers is the biological mechanism of the response by feline animals to silver vine. They hypothesized that the μ-opioid system, which is associated with euphoric effects in humans, is activated with the plant. "We tested β-endorphin levels before and after nepetalactol-induced response in cat blood. We found that silver vine activates the nervous system that is responsible for the euphorigenic reaction," said Miyazaki.

Does this mean cats play with silver vine to get euphoria? Alternatively, does silver vine has another function to cats? The research group believed that the plant has another biologically important function as the reaction was already shown in feline animals when they evolved from other species about 10 million years ago.

"On the basis of some reports that nepetalactone, the feline attractant in catnip, has mosquito repellent activity, we thought that the response allows cats to transfer plant's nepetalactol or nepetalactone on their fur for protection against mosquitoes. This led to a strong hypothesis when we found the mosquito repellent activity of nepetalactol." said Uenoyama.

To examine whether cats purposefully transfer nepetalactol, the research group placed paper filters with nepetalactol on different parts of the cat cage (floor, walls and ceiling). Although cats rubbed their faces and heads on the paper regardless of the place of the nepetalactol paper, they did not show the typical rolling when the paper was placed on a wall or ceiling. When cats rubbed against the nepetalactol paper, the substance was transferred to their faces and heads, indicating that the most important function of rubbing behavior is to apply the chemical to these parts of feline fur.

"Next, we tested the mosquito repellent property of nepetalactol on cats. We counted the numbers of mosquitoes landing on cat heads with and without application of nepetalactol. The mosquitoes landed less on the nepetalactol heads. To see whether mosquitoes react the same in a more natural setting, we compared the mosquito reaction between cats that responded to silver vine leaves and nonresponsive cats. Mosquitoes avoided the responsive cats. From these results, we found that the cats' reaction to silver vine is chemical defense against mosquitoes, and perhaps against viruses and parasitic insects. This was the most significant finding of our study," said Miyazaki.

Miyazaki and his colleagues see many possibilities to use the findings in research and practical application. "Why is this reaction limited to cats? Why don't non-feline animals react to the plant? To find answers, we want to identify the gene responsible for the reaction. The findings of this study may be used in various applications, including development of new mosquito repellant products."

Credit: 
Iwate University, Japan

New trial finds arthritis drug no better than standard care for severe covid-19

Adding the arthritis drug tocilizumab to standard care for patients in hospital with severe or critical covid-19 is no better than standard care alone in improving clinical outcomes at 15 days, finds a new trial published by The BMJ today.

There was an increased number of deaths at 15 days in patients receiving tocilizumab, resulting in the trial being stopped early.

Today's results contradict earlier observational studies suggesting a benefit of tocilizumab. However, observational effects are limited by a high risk that they may be due to other unknown (confounding) factors - and some studies have not yet been peer reviewed or published in a medical journal.

A randomised trial assessing tocilizumab in critically ill patients with covid-19 (REMAP-CAP) published as a preprint earlier this month, found a beneficial effect of the drug on days free from organ support within 21 days and mortality. Reasons for these apparently contradictory effects, for example differences between patients' characteristics, need to be assessed in future analysis, say the researchers.

Tocilizumab blocks a specific part of the immune system (interleukin 6) that can go into overdrive in some patients with covid-19. Doctors think this might help lessen the body's inflammatory response to the virus and avert some of the more dire consequences of the disease, but its effects are not well defined.

To test this theory, researchers based in Brazil conducted a randomised controlled trial comparing tocilizumab plus standard care with standard care alone in patients admitted to hospital with severe or critical covid-19.

Their findings are based on 129 relatively young adults (average age 57 years) with confirmed covid-19 at nine hospitals in Brazil between 8 May and 17 July 2020.

Patients were receiving supplemental oxygen or mechanical ventilation and had abnormal levels of at least two chemicals linked to inflammation in their blood.

Patients were randomly divided into two groups: 65 received tocilizumab plus standard care and 64 received standard care alone.

Other potentially important factors, such as underlying conditions and use of other medication, were taken into account and all patients were monitored for 15 days.

By day 15, 18 (28%) patients in the tocilizumab group and 13 (20%) in the standard care group were receiving mechanical ventilation or died.

Death at 15 days occurred in 11 (17%) patients in the tocilizumab group compared with 2 (3%) in the standard care group.

The increased number of deaths in the tocilizumab group raised safety concerns and the trial was stopped early. In both groups, deaths were attributed to covid-19 related acute respiratory failure or multiple organ dysfunction.

The researchers point to some limitations including the small sample size, which affects the chances of detecting a true effect. However, results were consistent after adjusting for levels of respiratory support needed by patients at the start of the trial, suggesting that the findings withstand scrutiny.

As such, the researchers conclude that in patients with severe or critical covid-19, "tocilizumab plus standard care was not superior to standard care alone in improving clinical status at 15 days and might increase mortality."

And they say these results "raise questions about an anti-inflammatory approach in the treatment of covid-19 beyond corticosteroids."

Credit: 
BMJ Group

Associations of government-mandated closures, restrictions with mobility, SARS-CoV-2 infections in Nigeria

What The Study Did: This observational study examined how COVID-19-related government-mandated closures and restrictions were associated with changes in mobility and the spread of COVID-19 in Nigeria.

Author: Daniel O. Erim, M.D., Ph.D., M.Sc., of Parexel International in Durham, North Carolina, is the corresponding author.

To access the embargoed study:  Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamanetworkopen.2020.32101)

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2020.32101?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=012021

About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

Credit: 
JAMA Network